Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Biology

Biochemistry

Medicine

Cancer Oncology

Immunology

Show all topics

DOI

10.1016/s0140-6736(17)32440-6

License

publisher-specific-oa